Redington Life Sciences News
Double Issue July 2020
In this issue: tooth enamel at the atomic level, CD47 in the news again, the elusive tequila bat, Mayo on Covid-19, dissing raw milk, ultrasound and lethal brain cancer, making kidneys safe to transport, Dana-Farber on DNA repair, reversing age in animals, super bugs and the gut, and more…
|A key gene modifies regulatory T cells to fine-tune the immune response
The human immune system is a finely-tuned machine, balancing when to release a cellular army to deal with pathogens, with when to rein in that army, stopping an onslaught from attacking the body itself. Now, researchers have discovered a way to control regulatory T cells, immune cells that act as a cease-fire signal, telling the immune system when to stand down.
|Why it’s no last orders for the Tequila bat: DNA helps conservation of elusive bat
Scientists studying the ‘near threatened’ tequila bat, best known for its vital role in pollinating the Blue Agave plant from which the drink of the same name is made from, have analysed its DNA to help inform conservationists on managing their populations.
|Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports
Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease and is on track to begin submitting a rolling New Drug Application to the FDA in the fourth quarter of 2020
|Yale, Cambridge pioneer new way to make kidneys safe for transplant
A new drug regimen may undo the effects of cold storage that make human kidneys unsuitable for transplant.
|Structural cells are key regulators of organ-specific immune responses
Structural cells implement a broad range of immune-regulatory functions beyond their roles as barriers and connective tissues, and they utilize an epigenetically encoded potential for immune gene activation in their rapid response to viral infection.
|TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
TG Therapeutics, Inc., announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting accelerated approval of umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL).
|Superbug impact on the gut
Monash University researchers discover how the bacterial superbug Clostridioides difficile hijacks the gut in order to cause serious and persistent disease
|Nearly 2 million California adults don’t get needed mental health care
A UCLA health policy brief recommends the expansion of Proposition 63 programs and services to address the unmet needs.
|Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Designation offers potential for expedited development and review Axsome now granted two Breakthrough Therapy designations for AXS-05 for separate CNS indications
|Complexity of human tooth enamel revealed at atomic level in NIH-funded study
Unprecedented details of enamel structure may point to new ways to prevent or halt cavities.
|Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics
Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development
|How the body regulates scar tissue growth after heart attacks
A single protein may determine the size of scars, scientists say. Larger scars heighten the risk of future death from heart failure.
|NIH investigators hope CD47 study leads to broad-spectrum infectious diseases immunotherapy
Finding provides a potential target for an immunotherapy that might be applied to a wide range of infectious diseases.
|Focused Ultrasound Shows Promise Against Deadliest Brain Tumor
Focused ultrasound waves create tiny bubbles inside cancer cells, causing them to die. The post appeared first on UVA Health Newsroom .
|Women who experience high blood pressure during pregnancy are more likely to develop heart disease
Between 1-6% of all pregnancies in Western countries are affected by high blood pressure, which usually returns to normal after giving birth. This condition is known as gestational hypertension, or pregnancy-induced hypertension. It differs from pre-eclampsia in that traces of protein are not found in the urine. Clinicians increasingly recognise that women who have had gestational hypertension
|News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer treatment
Science blog With news about the coronavirus pandemic developing daily, we want to make sure everyone affected by cancer gets the information they need during this time. We’re pulling together the latest government and NHS health updates from across the UK in a separate blog post , which we’re updating regularly. Targeted drug to treat multiple cancer types approved in England A targeted cancer
|An antiviral response beyond immune cells
Fibroblast, epithelial and endothelial cells are more than just the scaffold of an organ — it emerges that they communicate with immune cells and are primed to launch organ-specific gene-expression programs for antiviral defence.
|Females use anti-inflammatory T cells to keep their blood pressure down
In the face of a multipronged front to drive blood pressure up, including a high-salt diet, females are better able to keep their pressure down by increasing levels of a T cell that selectively dials back inflammation, scientists say.Y
|Raw milk may do more harm than good
Raw or unpasteurized cows' milk from U.S. retail stores can hold a huge amount of antimicrobial-resistant genes if left at room temperature, according to a new study.
|Universal gut microbiome-derived signature predicts cirrhosis
Researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.
|Why do arteries age? Study explores link to gut bacteria, diet
Eat a slab of steak and your resident gut bacteria get to work immediately to break it down. But new research shows that a metabolic byproduct, called TMAO, produced in the process can be harmful to the lining of arteries, making them age faster.
|New study examines recursive thinking
A multi-institutional research team found the cognitive ability to represent recursive sequences occurs in humans and non-human primates across age, education, culture and species.
|New class of safer analgesics discovered
Researchers have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys.
|Neurobiology: How much oxygen does the brain need?
The brain has a high energy demand and reacts very sensitively to oxygen deficiency. Neurobiologists have now succeeded for the first time in directly correlating oxygen consumption with the activity of certain nerve cells.
|Researchers use stem cells to model the immune response to COVID-19
Two members of the UCLA Broad Stem Cell Research Center have received a grant for work that could be helpful in developing a vaccine.
|Age-related impairments reversed in animal model
Researchers demonstrate in an animal model that age-related frailty and immune decline can be halted and even partially reversed using a novel cell-based therapeutic approach.
|Drug with new approach on impeding DNA repair shows promise in first clinical trial
In its first randomized clinical trial, a drug that targets a protein needed by cancer cells to maintain their dogged growth and division has shown considerable promise in combination with chemotherapy in patients with a common form of ovarian cancer, investigators at Dana-Farber Cancer Institute report.
|Some types of prostate cancer may not be as aggressive as originally thought
Research brief: Findings from a UCLA study indicate some men may not require the intensive treatment they have traditionally received.
Contact us at 212 926-1733 or at email@example.com
Ph: 212 926-1733 Email: firstname.lastname@example.org